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Genital infections with Chlamydia trachomatis (C. trachomatis) continue to be a worldwide epidemic. Immune response to
chlamydiaisimportanttobothclearanceofthediseaseanddiseasepathogenesis.Interindividualresponsesandcurrentchlamydial
controlprogramswillhaveenormouseﬀectsonthisdiseaseanditscontrolstrategies.HumoralimmuneresponsetoC.trachomatis
occurs in humans and persistent antibody levels appear to be most directly correlated with more severe and longstanding disease
and with reinfection. There is a close correlation between the presence of antichlamydial antibodies in females and tubal factor
infertility;theclosestassociationshavebeenfoundforantibodiesagainstchlamydialheatshockproteins.Thelatterantibodieshave
also been shown to be useful among infertile patients with prior ectopic pregnancy, and their presence has been correlated with
poor IVF outcomes, including early pregnancy loss. We review the existing literature on chlamydial antibody testing in infertile
patients and present an algorithm for such testing in the infertile couple.
1.Introduction
Chlamydia trachomatis (C. trachomatis) infection is one of
themostprevalentsexuallytransmitteddiseasesintheworld.
There were 409.2 cases per 100,000 population reported
in the United States in 2009 [1]. C. trachomatis is a
common cause of urethritis, epididymitis, prostatitis, cer-
vicitis, pelvic inﬂammatory disease, ectopic pregnancy, and
tubal factor infertility (TFI). As many as 80% of cases are
asymptomatic, particularly among females. This leads to
continued transmission of the infection to sexual partners
and the opportunity for chronic infection.
Pelvic inﬂammatory disease (PID), an ascending infec-
tion from the cervix to the peritoneal cavity, is diagnosed
in more than 800,000 women annually in the United States
[2]. The most widely accepted microbial etiologies of PID
are Neisseria gonorrhoeae and C. trachomatis [2–4]; still,
other pathogens have been implicated and the ﬁnal disease is
almost certainly polymicrobial. While C. trachomatis infec-
t i o nm a yb eac a u s a t i v ef a c t o ri nu pt o4 0 %o fc a s e so fP I D
[5],fairlyfewwomenwith C.trachomatisinthelowergenital
tract will progress to frank PID. The occurrence of symp-
tomatic PID after untreated C. trachomatis infections may
vary by population and time of followup but ranges between
less than 2 and 9.5% [6, 7]. Most infected women will
spontaneously clear their infections, although such clearance
may take well over a year after infection [6, 8]. Women who
do not clear their infections may suﬀer ascending infection
and expansion into the full PID syndrome.
Once inﬂammation occurs in the fallopian tube, epithe-
lial degeneration and deciliation of cells occur along the tube
[2]( Figure 1 [9]). Edema in the fallopian tube exacerbates
the intraluminal agglutination that occurs with endosalp-
ingitis and leads to clubbing of the ﬁmbriae and partial
or complete tubal obstruction. Peritonitis caused by C. tra-
chomatis can cause ﬁbrinous exudates on the serosal surface
of the uterus, fallopian tubes, and ovaries that fuses those
structures to themselves and to surrounding bowel and
omentum[2].Theseadhesionsarefrequentlyassociatedwith
chronic pelvic pain. Each subsequent episode of PID doubles
the risk for tubal factor infertility. Tubal pathology accounts
forapproximately14%ofsubfertility[10].Mostwomenwith2 Infectious Diseases in Obstetrics and Gynecology
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Figure 1: The eﬀects of C. trachomatis infection on human fallopian tubal morphology. Human fallopian tubes in organ culture were left
uninfected (a and b) or were infected with C. trachomatis serovar D (c and d). Ultrastructural analysis of the intratubal architecture uses
scanningelectronmicroscopy.Uninfected tubesaredenselyciliatedandcontainintactsecretorycells.Themucosalsurfaceof C.trachomatis-
infected tubes show remarkable deciliation and cellular disruption ([9] ,a n dr e p r o d u c e dw i t hp e r m i s s i o n ) .
tubal occlusion have no known history of sexually trans-
mitted infections. Evaluation of tubal infertility may include
serologic studies, hysterosalpingography, and laparoscopy.
Intrauterine dye infusion during laparoscopy is the gold
standard for assessing tubal occlusion, endometriosis, or
pelvicadhesionsininfertilitypatients.Laparoscopy,however,
is a costly invasive test that has risk for complications.
Hysterosalpingogram (HSG), a less costly and less compli-
cated imaging modality, has a sensitivity of 65–96% and
speciﬁcity of 73–83% for detecting tubal pathology [10–12].
This paper aims to evaluate the serologic tests available for
C. trachomatis and their associations with TFI.
2. Pathogenesis of Disease
C. trachomatis is an obligate intracellular bacterium that
produces a wide variety of clinical pathologies. Serovars D
through K are pathologic to mucosal epithelial cells of the
urogenital tract [13]. Erythema, edema, and mucopurulent
discharge can be seen on physical exam during acute infec-
tion [14]. Urethritis, epididymitis, prostatitis, cervicitis, and
pelvic inﬂammatory disease can develop following infection.
With chronic infection, cellular changes including ﬁbrosis
and mononuclear cell inﬁltration lead to increased risk for
ectopic pregnancy and TFI [14]. Both persistent infection
and re-infection with C. trachomatis may be associated with
worsening long-term sequelae, although the former appears
tobethemostconsequential[15].TheabilityofC.trachoma-
tis to transform repeatedly from the resting form (elemen-
tary body; EB) to the replicative form (reticulate body; RB)
enhances survival of the organism in the reproductive tract
[16]( Figure 2 [17]). The EB of C. trachomatis attaches to
the epithelial cell surface and incorporates into phagosomes
that migrate to the distal region of the Golgi complex
[13]. Lysosome fusion is prevented, and chlamydial infection
avertsimmediatedestruction.TheEBthendiﬀerentiatesinto
the noninfectious but replicative reticulate body (RB) which
further divides by binary ﬁssion [13]. Although C. trachoma-
tis can partially evade immune detection [18–24] making
infections fairly asymptomatic in many women, the infec-
tiousparticlescanberecognizedbythehost,withsubsequent
activation of host interferon (IFN-) γ and proinﬂammatoryInfectious Diseases in Obstetrics and Gynecology 3
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Figure 2: The life cycle of genital serovars of C. trachomatis. The chlamydial growth cycle involves transformation between distinct forms:
the elementary body (EB) and the reticulate body (RB). The highly infectious EB attaches to nonciliated columnar or cuboidal epithelial
cells and induces ingestion by the host cell. EB are metabolically inactive and represent the extracellular C. trachomatis growth form. Once
ingested into a phagosome, fusion of the phagosome with the host lysosome is prevented, a highly unusual occurrence that ensures EB
survival. The EB reorganizes within the phagosome into a metabolically active RB. RBs are noninfectious but can replicate and do so by
binary ﬁssion. Several stimuli, including antibiotic and IFNγ exposure, can drive chlamydia into a persistent state, which lasts in vitro until
removal of the exogenous stressor. If persistence is avoided, or if infection is reactivated from persistence, the RB will ultimately reorganize
back into EB, which will be released from the host cell to infect surrounding epithelial cells (reproduced with permission [17]).
cytokine secretion [25, 26]. In response to interferon expo-
sure in vitro, RB can enter a persistent and noninﬂammatory
state [26, 27]. Persistence can also be driven by nonsterilizing
antibiotic exposure in vitro [14, 25–27]. Although there
remainsnodirectinvivoevidenceforpersistenceinhumans,
clinical scenarios suggest that persistent infection may re-
main undetected for many years and reactivation may occur
much later in life. Reactivation may sometimes occur in
women with prior infections who are now no longer sexually
active or in women who have had their fallopian tubes
electively obstructed and no longer have a patent route from
lower to upper genital tract [14, 25, 28]. In the persistent
state, chlamydial heat shock protein 60 (CHSP60) genes are
upregulated and released [13, 29, 30]. In humans, elevated
antibody responses to CHSP60 have been strongly associated
with PID, ectopic pregnancy, scarring trachoma, and tubal
infertility [13, 25, 29, 30]. Long-term exposure to CHSP60
may lead to a loss of tolerance to cross-reactive endogenous
human antigens and generation of immune responses to
conserved amino acid sequences that are also expressed in
homologous human hsp60 [13, 25, 29, 30]. This immunity
can lead to immune responses against human hsp60 in the
early embryo and potentially link C. trachomatis infections
to spontaneous pregnancy loss (see the following).
It remains unclear why some women clear their infec-
tions, while others endure long-lasting, ascending, and pos-
sibly persistent infections. The human cytokine IFN-γ may
play a central role in this enigma. IFN-γ secretion by infected
cells and by those cells brought in to control infection is
centraltoinfectionclearance[6,31].IFN-γ isalsoinvolvedin
the tissue damage associated with C. trachomatis infections
[6, 31]. Finally, in vitro models use low to moderate level
IFN-γ exposure to drive C.trachomatispersistencewithreac-
tivation of the developmental cycle occurring after removal
of the exogenous IFN [27]. The level of immune response to
C.trachomatismaybeaﬀectedbymanyfactors.Alargeinitial
inoculation of infectious organisms may tip the balance
toward exuberant responses that may clear the infection
but be associated with more extensive damage. Genetic
diﬀerences among infected subjects may alter response to
infection. Several investigators have now reported on the
eﬀectsofsinglenucleotidepolymorphisms(SNPs)ininﬂam-
matory mediators, including cytokines, on the susceptibility
to C. trachomatis infection and on the severity of tubal
damageincurredduringsuchinfections[32,33].Thelevelof
oxygen within the fallopian tubes of C. trachomatis infected
women may alter the balance of IFN-mediated clearance
versus damage [34]. Reinfection may drive adverse infection
sequelae among women who have already developed amnes-
ticresponsestoC.trachomatis.Althoughsomewomenspon-
taneously lose antibody responses to chlamydial antigens
[35], antichlamydial IgG antibodies frequently persist for
prolonged periods of time, even among women who have
been treated with antibiotics [36, 37].
2.1.C.trachomatisAntibodiesandTFI. Severalimmunologic
techniques have been employed to study the relationship
betweentheresultsofC.trachomatisserologictestingandthe
severity of C. trachomatis-associated pathologies, including
TFI (summarized in Table 1). The most commonly studied
antibodies include those directed against chlamydial IgG and4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Role of antichlamydial antibody testing in male and female fertility.
Method Sens. (%) Specif. (%) PPV (%) NPV (%) Utility in females Utility in males
CT IgG [22] ELISA 72.7 77.7 — — Presence indicates previous
or persistent C. trachomatis
infection; associated with
tubal damage; increased
titers associated with more
severe tubal damage;
sens./specif. may be
increased with the addition
of HSG or laparoscopy
—
CT IgG [33] ELISA 43.2 86.5 63.3 73.8 —
CT IgG [6] MIF 74 93 94.8 69.8 —
CT IgG [5] EIA 45 83 — — —
CT IgG [23]
Titer > 1:256 WIF 69 85 78 78
—
CT HSP60 [33] ELISA 59.1 77.9 59.1 77.9
Reﬂects chronic
C. trachomatis infection;
predicts TFI
—
CT HSP60 [7] GST
ELISA 56 95 — —
Higher titers related to
increased severity of tubal
damage
—
+ClpP Ab [7] GST
ELISA 69 — 92 79 Improve sens./specif. in Ab
based diagnosis of TFI —
CT IgA [28, 29] MIF/EIA — — — — —
Reduces chances of
achieving pregnancy;
reduced motility of
spermatozoa, increased
number of dead
spermatozoa
+CT IgG [28, 29] MIF/EIA — — — — —
Further reduce pregnancy
rates, decrease sperm
concentration, decrease
number of progressive
spermatozoa
CT HSP60 [29] ELISA — — — — — Reduce spermatozoa
motility
ELISA: enzyme-linked immunosorbent assay, EIA: enzyme immunoassay, WIF: whole-cell inclusion immunoﬂuorescence assay, GST ELISA: glutathione S-
transferaseELISA,MIF:microimmunoﬂuorescence,Ab:antibody;Sens.:sensitivity,Specif.:speciﬁcity,PPV:positivepredictivevalue,NPV:negativepredictive
value; TFI: tubal factor infertility; HSG: hysterosalpingogram.
CHSP60. The results of each of these investigations must
be interpreted with caution, as the methodologies used to
detect antibodies vary in their utility and the populations
studied may vary in their genetic predisposition to immune
responsivity and antibody production and persistence. Still
the results appear to trend similarly. Elevated antichlamydial
antibody levels can be found in >70% of women with tubal
occlusion [12]. Malik et al. [38] evaluated IgG antibodies to
C. trachomatis using enzyme-linked immunosorbent assays
(ELISAs) and found that 63.6% of those with positive IgG
serologies had tubal occlusion on HSG. This results in a
sensitivity of 72.7% and speciﬁcity of 44.4% for tubal
occlusion [38]. Perquin et al. [10] evaluated the presence of
antichlamydial IgG antibodies using species-speciﬁc enzyme
immunoassay (EIA) and compared these levels to ﬁndings of
HSG and at laparoscopy. The sensitivity and speciﬁcity for
IgG antibodies using EIA in predicting tubal pathology were
found to be 45% and 83%, respectively [10]. Akande et al.
[39] evaluated antichlamydial IgG antibodies using single-
antigen inclusion tests and indirect immunoﬂuorescence
(whole-cell inclusion immunoﬂuorescence; WIF). Antibody
titers were found to be signiﬁcantly higher among infertile
women who had previously conceived compared to those
with primary infertility [39]. This seemingly contradictory
ﬁnding may be related to increased risk factors for sexually
transmitted infections, including increased numbers of sex-
ual partners, in those with secondary infertility, or with
higher prevalence of other causes of infertility (e.g., anovu-
lation or endometriosis) in those with primary infertility.
Titers were signiﬁcantly higher among those with a history
of PID and those with documented tubal pathology. A linear
relationship was observed between antibody titer level and
the likelihood of tubal damage. Patients with the highest
titers(>1:4096)hada100%rateoftubaldamage,and73.1%
of those had severe tubal damage [39]. Negative antibody
testing did not preclude the diagnosis of tubal damage.
den Hartog et al. [40] evaluated subfertile women with
chlamydial antibody testing (CAT) involving antichlamydial
Ig ELISA and high-sensitivity C-reactive protein (hsCRP)
ELISA and compared the results to tubal evaluations using
HSG. Seropositivity for IgG antibodies reﬂects previous
C.trachomatisinfection,whilethepresenceofhsCRPreﬂectsInfectious Diseases in Obstetrics and Gynecology 5
persistence of the infection. They found that the addition of
HSG was of limited value in predicting tubal pathology in
women who were CAT positive or CAT and hsCRP positive.
Rodgers et al. [12] reported that TFI patients had higher
titer levels of antichlamydial antibodies than either women
in infertile control couples without TFI or in fertile control
couples [12]. They also found that antibodies against ClpP
were signiﬁcantly higher in the TFI group compared to
controls. ClpP is a proteolytic subunit of the ATP-dependent
Clpproteasecomplexthatispartofahighlyconservedserine
protease family in eukaryotes and bacteria [12]. Chlamydial
ClpP displays a 45% amino acid sequence identity with its
homolog in humans. It is hypothesized that human anti-
chlamydial ClpP antibodies can recognize cross-reactive
epitopes and attack human ClpP in tissues [12].
Heat shock proteins (HSPs) are stress response proteins
found in humans, animals, and bacteria. Expression of HSPs
increases with temperature changes, ischemia, or hypoxia
[12, 29, 30]. They have also been implicated in cell trans-
formation and the development of metastatic potential and
multidrug resistance [41]. HSPs contain amino acid regions
that are highly conserved among the organisms that express
them. Antibodies to CHSP60 have been linked to TFI
in numerous studies [12, 25, 29, 30, 41]. CHSP60 stim-
ulates inﬂammatory responses, including activation of
macrophages and epithelial cells to secrete the inﬂamma-
tory cytokines, IFN-γ and tumor necrosis factor-α (TNF-
α), as well as other proinﬂammatory mediators [12, 41].
Stimulation of endothelial cells, smooth muscle cells, and
macrophages leads to the production of adhesion factors
and proinﬂammatory cytokines by activation of nuclear
factor-κB( N F - κB) [41]. Jakus et al. [42] reported on the
presence of anti-CHSP60 IgG antibodies in the follicular
ﬂuid of patients who had previously undergone IVF. Anti-
CHSP60 antibodies were detected in 74.1% of women with
implantation failure; 47.9% of those with 1–3 implantations
per IVF cycle were anti-CHSP60 positive. Among women
with documented tubal occlusion, 69.5% were antibody
positive, while only 49.7% of women with other causes
of infertility had anti-CHSP60 antibodies [42]. In another
study, the presence of anti-HSP60 antibodies predicted TFI
with a sensitivity of 56% but a speciﬁcity of 95%. Inclusion
of anti-ClpP antibody testing increased the sensitivity to
69% [12]. The negative predictive value of ClpP and HSP60
for TFI was 79% and positive predictive value 92% [43].
Keltz et al. [11] assessed the sensitivity and speciﬁcity of
HSG alone and HSG combined with CAT to detect tubal
occlusion when compared to laparoscopy. HSG alone had
sensitivity of 78% and speciﬁcity of 82%, while CAT alone
had excellent positive predictive value of 94.8% but a poor
negative predictive value of 69.8% due to its low sensitivity
of 74%. This sensitivity increased to 97.3% when CAT results
were combined with those of HSG. Laparoscopy, however,
found pelvic pathologies other than tubal occlusion in 33–
68% of patients with a normal HSG [11].
El Hakim et al. [44] evaluated 408 women with doc-
umented tubal damage on laparoscopy and compared the
severity of damage with antibody titer levels using WIF. Sim-
ilar to the results of the Keltz study [11], the severity of tubal
damage was found to correlate signiﬁcantly with increasing
serum antibody levels [11, 44]. Bipolar and distal tubal
occlusionwerefoundtohavethehighestantibodytiters[44].
VanTeteringetal.[45]evaluated711womenwithknown
anovulation and compared their antichlamydial antibody
titers using ELISA with tubal pathology diagnosed using
either HSG or laparoscopy. CAT screening yielded a sensitiv-
ity and speciﬁcity for tubal damage of 20% and 89%, respec-
tively. However, the prevalence of CAT positivity was <5%,
suggesting limited value for CAT screening in infertile
women with known etiologic factors, particularly anovula-
tion [45].
2.2. C. trachomatis Antibodies and Male Factor Infertility.
While women can develop PID after C. trachomatis infec-
tions, men can develop urethritis, epididymitis, orchitis, and
proctitis.Epididymitis canleadtocanalicularsystemdamage
and obstructive azoospermia, although such severe post-
chlamydial outcomes are uncommon. C. trachomatis infec-
tions more commonly result in the generation of antisperm
antibodiesandchangesinsemenqualitythatdiminishrather
than prevent male fertility. Detection of anti-C. trachomatis
IgA and IgG antibodies, but not anti-HSP60 IgG antibodies,
in male serum has been associated with poor semen char-
acteristics and pregnancy rates regardless of female partner
antibody status [46, 47] (summarized in Table 1). In one
investigation, the presence of serum antichlamydial IgA,
alone or in combination with IgG, correlates with reduced
concentration and progressive motility of spermatozoa, an
increase in the number of dead spermatozoa, poor sperm
morphology, and a higher prevalence of leukocytospermia
[46]. Men with IgG alone or IgA alone decrease their chance
of achieving pregnancy by a third; men with both serum
antibodies decrease their chances by almost two-thirds [46].
Interestingly, these reductions were completely surmounted
through the use of in vitro fertilization (IVF). Not all investi-
gators have replicated these ﬁndings. Eggert-Kruse et al. [48]
examined male serum and seminal plasma from subfertile
couples for antichlamydial IgA, IgG, and IgM antibodies
using chlamydial lipopolysaccharide- (LPS-) directed ELISA.
Although the presence of IgA antibodies in seminal ﬂuid was
associatedwithantibodydetectionintheserumofthefemale
partners, the ﬁndings did not correlate with reduced sperm
count or motility or subsequent fertilizing capacity [48].
2.3. C. trachomatis Antibodies and Pregnancy Outcomes.
Antibodies to C. trachomatis and CHSP60 are strongly
associated with TFI. Individuals with known TFI commonly
undergo in vitro fertilization to overcome their tubal pathol-
ogy, but they may still be at risk for adverse obstetric out-
c o m e ss u c ha ss p o n t a n e o u sa b o r t i o no rb i o c h e m i c a lp r e g -
nancy [13]. Among 174 women with normal fallopian tubes
at laparoscopy who were followed for 3 years, the presence
of antichlamydial antibodies using immunoﬂourescence
(38.5%) was not predictive of obstetric outcomes [49]. The
riskappearstobehigherinthepresenceofantibodiesspeciﬁc
to CHSP60. Human hsp60 is expressed during early embryo
development and normally does not trigger an immune6 Infectious Diseases in Obstetrics and Gynecology
response[13,42].Heatshockproteinsofvariousspeciescon-
tain a highly conserved region of amino acids. Sensitization
to this conserved region in CHSP60 can result in reactivation
of previously tolerized HSP60-speciﬁc lymphocytes. This
may, in turn, compromise fetal or maternal cell viability
via the direct activity of anti-HSP60 antibodies and/or the
accompanying proinﬂammatory response. In 1999, Witkin
[50] reported that women with cervical antichlamydial and
anti-CHSP60 IgA antibodies were less likely to have a live
birth after in vitro fertilization than their counterparts who
did not have these antibodies. Patients undergoing IVF do
not require patent or normal fallopian tubes. The rate of
very early pregnancy loss was 3 times greater among those
women who were anti-CHSP60 positive. Further, incubation
ofembryosinmediacontaininghumanserapositiveforanti-
human HSP60 antibodies inhibited embryo development
[50]. Supporting these results, Jakus et al. [42] studied 253
IVF patients and demonstrated lower implantation rates
among women with follicular ﬂuid anti-CHSP60 antibodies
when compared with antibody negative controls. No diﬀer-
ences were detected in the number of oocytes collectedor the
percentage that fertilized.
Among women less than 35 years of age with a his-
tory of ectopic pregnancy treated with salpingectomy, the
presence of serum anti-CHSP60 antibodies predicted lower
spontaneous conception rates and decreased term delivery
rates [51]. The same study reported that circulating IgG
antibodies to a conserved epitope of CHSP60 (amino
acids 260–271) were associated with decreased spontaneous
fertility, repeated ectopic pregnancy, and adverse subsequent
pregnancy outcome, suggesting that damage to the remain-
ing tube may have occurred prior to the salpingectomy
[51]. Women without antibodies to CHSP60 260–271 were
ﬁve times more likely to have documented intrauterine
conceptions and term deliveries when compared to those
withpositiveserologies[51].Womenwithpositiveserologies
might therefore consider IVF after a ﬁrst ectopic pregnancy
to improve conception and pregnancy outcomes.
2.4. Use of Chlamydial Antibody Screening in Couples
with Infertility. Despite several continuing controversies, the
existing data on the relationship between antichlamydial
antibodies and tubal factor infertility make consideration
of algorithms for screening possible (Figure 3). Chlamydial
antibody screening is inexpensive when compared to other
methods of tubal evaluation (HSG) but oﬀers similar or
improved sensitivity and speciﬁcity. HSG is more likely to
be associated with adverse sequelae among women with
chlamydial antibodies [40].
In our proposed algorithm, couples presenting with
infertility would be screened ﬁrst with careful histories
and physical exams. If the female partner has a history
of ectopic pregnancy, testing for anti-CHSP60 antibodies
could be performed. Those with positive antibodies may be
counseled to consider progression towards IVF to optimize
their chance for a live birth. Couples without such a history
would undergo documentation of ovulatory function and
semen analysis. If the female was anovulatory, but the semen
analysis was normal, the woman could consider ovulation
induction and timed intercourse for 3-4 cycles prior to
further interventions. If the woman was anovulatory or had
normal ovulatory function, but the semen analysis revealed
severe abnormalities, IVF would be recommended. If the
semen analysis revealed persistent mild to moderate abnor-
malities, referral to an urologist could be considered and 3-4
cycles of timed intrauterine insemination undertaken prior
to further evaluation. This would be combined with ovula-
tion induction in anovulatory women. Couples with normal
ovulation and normal semen parameters would be oﬀered
antichlamydial antibody testing (CAT). The signiﬁcant body
of literature linking CAT to TFI using anti- chlamydial major
outer membrane proteins (MOMPs) antibodies warrants
preliminary screening with standard CAT. Despite reports
that CAT antibody levels can be associated with severity of
tubal disease, the wide variations in antibody levels among
aﬀected patients reduce our enthusiasm for using antibody
titer levels in management decisions at this time [44]. If
CAT using MOMP is positive, laparoscopy would be recom-
mended; if negative, testing for antibodies against CHSP60
(and possibly chlamydial Clp protease; ClpP) would be per-
formed. Those positive for antichlamydial antibodies would
proceed directly to laparoscopy for diagnosis and treatment.
If normal fallopian tubes were found at laparoscopy, the cou-
plecouldbetreatedusingstandardprotocolsforunexplained
infertility [49]. Those negative for antibodies could also be
treated for unexplained infertility.
This suggested algorithm may be improved as additional
antibodytargetsonchlamydiaareidentiﬁedandmayneedto
be modiﬁed in light of current worldwide eﬀorts to control
the chlamydia epidemic [6, 52, 53]. Accompanying these
control eﬀorts are decreases in postinfection sequelae but
continued increases in infection prevalence. It is possible
that early identiﬁcation and treatment of C. trachomatis
infections is interrupting not only the destructive immune
response to the pathogen but the protective response as well,
a phenomenon that has been called “the arrested immunity
hypothesis” [54]. Partner treatment may therefore be an
important part of control paradigms as reinfection may
become increasingly common. Does this arrested immunity
result in reduced levels of protective IFN-γ thatmaypromote
persistence in some individuals? Arrested immunity might
hinder antibody responses and make persistence of anti-
bodies less common among previously infected but treated
women. This may have little eﬀect on screening programs if
these women also avoid persistent infections. We do not
presently have a deﬁnitive answer to these questions. Antibi-
otics such as penicillin and sulfonamides have been demon-
strated to drive the development of chlamydial persistence in
vitro [55]. Incomplete antibiotic therapy in areas that do not
have availability of single-dose regimens might be predicted
to promote persistence in vivo. Continued surveillance of
chlamydial antibody screening programs for infertile couples
will be key to monitoring the eﬀects of control programs on
the utility of screening.Infectious Diseases in Obstetrics and Gynecology 7
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Figure 3: A proposed algorithm for use of chlamydial antibody screening in infertile couples.
3. Conclusion
C. trachomatis is one of the most prevalent sexually trans-
mitted infections in the United States and worldwide. Long-
term sequelae of C. trachomatis infection include pelvic
inﬂammatory disease, tubal factor infertility, and risk of
ectopic pregnancy. Antibody testing for both antichlamydial
IgG and anti-CHSP60 has been found to be associated with
TFI. Increasingly high titers of antichlamydial IgG and anti-
CHSP60 antibodies have been correlated with increasing
severity of tubal damage when evaluated using HSG or
laparoscopy. While sensitivity and speciﬁcity for CAT are
comparable to that of HSG alone, CAT is less cost prohibitive
and has less risks than either HSG or laparoscopy. CAT
may be a valuable screening test prior to laparoscopy in
infertility patients. Chlamydial antibodies have also been
associated with male factor infertility, including reductions
inspermmotilityandtotalspermcounts.ChlamydialHSP60
antibodies have also been shown cross-react with human
HSP60. This may lead to immune destruction of the early
embryo and pregnancy wastage among women previously
infected with C. trachomatis. Chlamydia antibody testing is
a low-risk screening modality with sensitivity and speciﬁcity
comparable to HSG and should be considered in the initial
infertility evaluation. Limitations of CAT include (1) an
inability to identify women with noninfectious causes of
TFI, such as endometriosis, previous pelvic surgeries, or
peritonitis, requiring these women to proceed with HSG or
laparoscopy; (2) the possibility of declining antibody titers
over time; (3) the ability to detect high titers among some
women with normal appearing fallopian tubes; (4) the prob-
ability that additional antibody targets will be deﬁned that
improve screening sensitivity and speciﬁcity; (5) the un-
known eﬀects of chlamydial control programs on the utility
of antibody testing among infertile couples.
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